[2]naphthyl-maleic acid-anhydride | 92103-67-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: [2]naphthyl-maleic acid-anhydride
• 英文别名: [2]Naphthyl-maleinsaeure-anhydrid；3-(Naphthalen-2-yl)furan-2,5-dione；3-naphthalen-2-ylfuran-2,5-dione
• CAS: 92103-67-8
• 化学式: C₁₄H₈O₃
• 分子量: 224.216
• InChiKey: RNORNIMLCLHFQN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  [2]naphthyl-maleic acid-anhydride 在 palladium on activated charcoal 氢气 作用下， 生成 dimethyl 2-(2-naphthyl)succinate
  参考文献：
  名称：

  Photochemical reactions of dimethyl acetylenedicarboxylate with benzene and naphthalene

  摘要：

  DOI：

  10.1021/jo01260a035
• 作为产物：
  描述：

  在 甲酸 、 硫酸 作用下， 生成 [2]naphthyl-maleic acid-anhydride
  参考文献：
  名称：

  激发态光化学[2+4]-二聚反应

  摘要：

  芳基马来酰亚胺经历意想不到的[2+4]-光二聚化的新颖发散激发态反应性被提出，并具有详细的机制原理。形成的光二聚体的立体化学与在热条件下观察到的产物互补，并且由光激发反应物中普遍存在的非键相互作用的类型决定。

  DOI：

  10.1002/anie.202316662

文献信息

• Rhodium(<scp>iii</scp>)-catalysed decarbonylative coupling of maleic anhydrides with alkynes
  作者：Takanori Matsuda、Kentaro Suzuki

  DOI：10.1039/c4ra06452f

  日期：——

  A formal [5 − 1 + 2] annulation for the preparation of substituted α-pyrones is reported. The reaction involves the decarbonylative coupling of substituted maleic anhydrides with internal alkynes in the presence of a rhodium(III) catalyst and a copper(II) salt, affording tri- and tetrasubstituted α-pyrones.

  据报道，正式的[5-1 + 2]环化法制备了取代的α-吡喃酮。该反应涉及在铑（III）催化剂和铜（II）盐存在下，取代的马来酸酐与内部炔烃的脱羰基偶联，得到三和四取代的α-吡喃酮。
• NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM
  申请人：Pelletier Jeffrey Claude

  公开号：US20090054392A1

  公开（公告）日：2009-02-26

  The present invention relates to naphthylpyrimidine analogs, methods of making naphthylpyrimidine analogs, compositions comprising a naphthylpyrimidine analog, and methods for treating canonical Wnt-β-catenin cellular messaging system-related disorders comprising administering to a subject in need thereof an effective amount of a naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analog.

  本发明涉及萘基嘧啶类似物、制备萘基嘧啶类似物的方法、包含萘基嘧啶类似物的组合物以及治疗与经典Wnt-β-catenin细胞信息传递系统相关的疾病的方法，包括向需要治疗的受试者投予有效量的萘基嘧啶、萘基吡嗪和萘基吡啶类似物。
• Denivelle; Razavi, Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences, 1953, vol. 237, p. 570
  作者：Denivelle、Razavi

  DOI：——

  日期：——
• Synthesis and Pharmacological Characterization of Bicyclic Triple Reuptake Inhibitor 3-Aryl Octahydrocyclopenta[<i>c</i>]pyrrole Analogues
  作者：Liming Shao、Michael C. Hewitt、Scott C. Malcolm、Fengjiang Wang、Jianguo Ma、Una C. Campbell、Nancy A. Spicer、Sharon R. Engel、Larry W. Hardy、Zhi-Dong Jiang、Rudy Schreiber、Kerry L. Spear、Mark A. Varney

  DOI：10.1021/jm101312a

  日期：2011.8.11

  The present work expands the chemical space known to offer potent inhibition of the serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine transporter (DAT) and discloses novel bicyclic octahydrocyclopenta[c]pyrrole and octahydro-1H-isoindole scaffolds as potent triple reuptake inhibitors (TRIs) for the potential treatment of depression. Optimized compounds 22a (SEAT, NET, DAT, IC(50) = 20, 109, 430 nM), 23a (SERT, NET, DAT, IC(50) = 29, 85, 168 nM), and 26a (SERT, NET, DAT, IC(50) = 53, 150, 140 nM) were highly brain penetrant, active in vivo in the mouse tail suspension test at 10 and 30 mpk PO, and were not generally motor stimulants at doses ranging from 1 to 30 mpk PO. Moderate in vitro cytochrome P450 (CYP) and potassium ion channel Kv11.1 (hERG) inhibition were uncovered as potential liabilities for the chemical series.
• [EN] NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM<br/>[FR] ANALOGUES DE NAPHTYLPYRIMIDINE, NAPHTYLPYRAZINE ET NAPHTYLPYRIDAZINE ET LEUR UTILISATION COMME AGONISTES DU SYSTÈME DE COMMUNICATION CELLULAIRE WNT-BÊTA-CATÉNINE
  申请人：WYETH CORP

  公开号：WO2009026319A1

  公开（公告）日：2009-02-26

  The present invention relates to naphthylpyrimidine analogs, methods of making naphthylpyrimidine analogs, compositions comprising a naphthylpyrimidine analog, and methods for treating canonical Wnt-[beta-symbol]-catenin cellular messaging system-related disorders comprising administering to a subject in need thereof an effective amount of a naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analog.